The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells

Gemcitabine, an inhibitor of DNA synthesis, is the gold standard chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC). MicroRNAs (miRNAs) play critical roles in cancers, including PDAC. However, less is known about the effect of gemcitabine on PDAC cells and miRNA expression in PDAC. W...

Full description

Saved in:
Bibliographic Details
Published in:In vivo (Athens) 2020-11, Vol.34 (6), p.3195-3203
Main Authors: Namima, Daisuke, Fujihara, Shintaro, Iwama, Hisakazu, Fujita, Koji, Matsui, Takanori, Nakahara, Mai, Okamura, Megumi, Hirata, Masahiro, Kono, Toshiaki, Fujita, Naoki, Yamana, Hiroki, Kato, Kiyohito, Kamada, Hideki, Morishita, Asahiro, Kobara, Hideki, Tsutsui, Kunihiko, Masaki, Tsutomu
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gemcitabine, an inhibitor of DNA synthesis, is the gold standard chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC). MicroRNAs (miRNAs) play critical roles in cancers, including PDAC. However, less is known about the effect of gemcitabine on PDAC cells and miRNA expression in PDAC. We evaluated the effect of gemcitabine on the cell cycle of PDAC cells in vitro and in vivo and on the miRNA expression profile. Effects of gemcitabine on PK-1 and PK-9 cell growth were evaluated using a cell counting kit-8 assay. Xenografted mouse models were used to assess gemcitabine effects in vivo. Gemcitabine inhibited the proliferation and tumour growth of PK-1 cells, and induced S phase cell cycle arrest. Numerous miRNAs were altered upon gemcitabine treatment of PK-1 cells and xenograft models. Altered miRNAs may serve as potential therapeutic targets for improving the efficacy of gemcitabine in PDAC.
ISSN:0258-851X
1791-7549
DOI:10.21873/invivo.12155